Blueberries Medical (BBM) AI Stock Analysis

• Market Cap: C$7.43M
• Dividend Yield: N/A
• Average Volume (3M): 12.65K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.46
• Revenue Growth: 46.27%
• EPS Growth: 20.75%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 495,090,100
• 10 Day Avg. Volume: 7,006
• 30 Day Avg. Volume: 12,650
• PEG Ratio: -0.26
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Blueberries Medical's overall score reflects significant financial performance challenges, with ongoing losses and cash flow issues. However, the recent capital infusion and technical indicators offer some optimism. The stock valuation remains unattractive, primarily due to negative earnings, making it less appealing for value investors.

Blueberries Medical Business Overview & Revenue Model

Company Description

Blueberries Medical Corp. (BBM) is a Latin American cannabis company focused on the cultivation, processing, and distribution of medical cannabis products. Operating primarily in Colombia, the company leverages favorable climatic conditions and regulatory frameworks to produce high-quality cannabis derivatives. Blueberries Medical aims to be a leading supplier of cannabis-based health and wellness products in the region, catering to both domestic and international markets.

How the Company Makes Money

Blueberries Medical makes money through the cultivation and sale of cannabis products, primarily targeting the medical and wellness sectors. The company generates revenue by selling cannabis derivatives such as oils, extracts, and other infused products to pharmaceutical companies, healthcare providers, and wellness brands. Additionally, Blueberries Medical may enter into strategic partnerships or licensing agreements to expand its distribution network and enhance its market reach. Key factors contributing to its earnings include its ability to produce cannabis at a low cost due to Colombia's favorable growing conditions and its compliance with international regulatory standards, enabling access to export markets.

Blueberries Medical Financial Statement Overview

Summary

The company faces significant profitability challenges with negative net profit and cash flow margins despite revenue growth. Operational inefficiencies and cash burn issues are notable, posing risks to financial stability.

Income Statement

Blueberries Medical has shown some progress in revenue growth but continues to face significant profitability challenges. The gross profit margin has fluctuated but remains low, indicating efficiency issues. The net profit margin is negative, highlighting ongoing losses. Despite revenue growth, the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position, although it has faced declining total assets over recent years. The debt-to-equity ratio is low, suggesting conservative leverage use. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is healthy, showing good asset financing through equity.

Cash Flow

Cash flow analysis reveals significant negative operating cash flow and free cash flow, reflecting ongoing cash burn issues. The free cash flow to net income ratio is concerning, as it indicates inefficiencies in converting net income into cash. The operating cash flow to net income ratio is negative, showing issues in operational cash generation relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	471.41K	288.27K	235.45K	138.75K	65.98K
Gross Profit	59.32K	84.22K	-17.72K	-245.45K	62.40K
EBITDA	-1.04M	-1.22M	-811.47K	-4.05M	-4.11M
Net Income	-1.15M	-1.64M	-917.58K	-5.32M	-4.98M
Balance Sheet
Total Assets	1.38M	2.42M	3.35M	3.59M	7.27M
Cash, Cash Equivalents and Short-Term Investments	66.08K	818.16K	1.41M	1.34M	306.51K
Total Debt	11.44K	12.80K	1.34M	1.44M	1.49M
Total Liabilities	545.61K	470.72K	1.89M	2.16M	3.38M
Stockholders Equity	834.81K	1.95M	1.47M	1.43M	3.89M
Cash Flow
Free Cash Flow	-796.85K	-1.35M	-1.47M	-1.73M	-3.00M
Operating Cash Flow	-796.85K	-1.33M	-1.47M	-1.68M	-2.39M
Investing Cash Flow	9.00K	382.92K	101.94K	-48.77K	-611.04K
Financing Cash Flow	-1.95K	539.10K	1.35M	2.77M	783.92K

Blueberries Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.91 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	60 Neutral	C$6.88M	181.82	-3.45%	―	4.04%	80.24%
BBM	53 Neutral	C$7.43M	―	-112.06%	―	46.27%	20.75%
CANB	51 Neutral	C$5.53M	80.00	0.83%	―	-8.84%	-96.82%
IMCC	51 Neutral	$9.13M	―	-63.75%	―	9.34%	69.69%
ATLE	46 Neutral	C$88.06M	―	-971.43%	―	571.23%	64.25%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%

Blueberries Medical Corporate Events

Blueberries Medical Secures C$1 Million for Expansion

Blueberries Medical Corp. announced a C$1 million non-brokered private placement to fund and expand its operations. The offering is led by Terraflos Inc., which is exploring expansion in Latin America. This move is expected to enhance Blueberries’ operational capabilities and strengthen its market position in the medicinal cannabis industry.